-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Wang Bo and his delegation from Yaorongquan visited Kexuan Pharmaceutical to jointly explore industry trends and chart a new course for future development.
Publish Time:
2026-01-04
On January 14, Wang Bo, founder and chairman of Yaorongquan, and his delegation visited Keyuan Pharmaceutical and Linuo Pharmaceutical. The two sides conducted an in-depth inspection and held a symposium to discuss topics such as industry development trends, corporate product planning, and business strategy. Li Hongfu, chairman of Keyuan Pharmaceutical, and Gao Chunpo, president of the company, accompanied the delegation on the visit and jointly participated in this industry exchange.
On January 14, Wang Bo, founder and chairman of Yaorongquan, and his delegation visited Kexuan Pharmaceutical & Linuo Pharmaceutical (stock code: 301281.SZ). The two sides conducted an in-depth inspection and held a symposium to discuss industry development trends, corporate product planning, and business strategies. Li Hongfu, chairman of Kexuan Pharmaceutical, and Gao Chunpo, president, accompanied the delegation on the visit and jointly participated in this industry exchange.
At the outset of the inspection, Chairman Wang Bo and his delegation visited the intelligent manufacturing project for injectable drugs at Linuo Pharmaceutical. They toured the automated production line for injectables, the intelligent quality-control system, and the production management platform firsthand. They highly praised the project’s large-scale, intelligent production capabilities and its comprehensive, end-to-end quality control system.
During the roundtable discussion, Chairman Li Hongfu warmly welcomed Chairman Wang Bo and his delegation, and provided a detailed introduction to the company’s development journey, its core business layout, and its future strategic plans. He pointed out that Keyuan Pharmaceutical, as a publicly listed company specializing in the R&D, production, and sales of chemical APIs, formulations, and pharmaceutical intermediates, boasts solid technological strengths and stable market competitiveness in its industry sector. The company will continue to focus on its core business, optimize its product portfolio, and drive R&D innovation. On the basis of compliance and quality control, it will explore more sustainable development models and enhance its long-term competitiveness.
Chairman Wang Bo, drawing on industry development trends, shared insights into the pharmaceutical sector’s evolving trajectories across multiple dimensions—including policy, market dynamics, and technology—and analyzed potential pathways for industrial upgrading and structural optimization. Both sides engaged in an in-depth discussion on the industry’s future direction, corporate strategic choices, and product-line planning, and reached a consensus on strengthening industry collaboration and promoting mutually beneficial value creation.
This exchange has established an efficient collaboration bridge between Yaorongquan and Keyuan Pharmaceutical & Linuo Pharmaceutical. Taking this symposium as an opportunity, both sides will accelerate the implementation of their cooperation, focusing on product planning, strategic alignment, and innovation in development models. By fully leveraging their respective resource advantages, they will jointly explore effective pathways for high-quality development of pharmaceutical enterprises, thereby making positive contributions to driving the transformation and upgrading of China’s pharmaceutical industry and advancing its integration into the global market.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline